235 related articles for article (PubMed ID: 26232493)
1. Unliganded EphA3 dimerization promoted by the SAM domain.
Singh DR; Cao Q; King C; Salotto M; Ahmed F; Zhou XY; Pasquale EB; Hristova K
Biochem J; 2015 Oct; 471(1):101-9. PubMed ID: 26232493
[TBL] [Abstract][Full Text] [Related]
2. The SAM domain inhibits EphA2 interactions in the plasma membrane.
Singh DR; Ahmed F; Paul MD; Gedam M; Pasquale EB; Hristova K
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):31-38. PubMed ID: 27776928
[TBL] [Abstract][Full Text] [Related]
3. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.
Lisabeth EM; Fernandez C; Pasquale EB
Biochemistry; 2012 Feb; 51(7):1464-75. PubMed ID: 22242939
[TBL] [Abstract][Full Text] [Related]
4. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
London M; Gallo E
Mol Biol Rep; 2020 Jul; 47(7):5523-5533. PubMed ID: 32621117
[TBL] [Abstract][Full Text] [Related]
5. Low frequency mutation of the Ephrin receptor A3 gene in hepatocellular carcinoma.
Bae HJ; Song JH; Noh JH; Kim JK; Jung KH; Eun JW; Xie HJ; Ryu JC; Ahn YM; Kim SY; Lee SH; Yoo NJ; Lee JY; Park WS; Nam SW
Neoplasma; 2009; 56(4):331-4. PubMed ID: 19469653
[TBL] [Abstract][Full Text] [Related]
6. Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling.
Lawrenson ID; Wimmer-Kleikamp SH; Lock P; Schoenwaelder SM; Down M; Boyd AW; Alewood PF; Lackmann M
J Cell Sci; 2002 Mar; 115(Pt 5):1059-72. PubMed ID: 11870224
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen.
Smith FM; Vearing C; Lackmann M; Treutlein H; Himanen J; Chen K; Saul A; Nikolov D; Boyd AW
J Biol Chem; 2004 Mar; 279(10):9522-31. PubMed ID: 14660665
[TBL] [Abstract][Full Text] [Related]
8. Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization.
Lackmann M; Oates AC; Dottori M; Smith FM; Do C; Power M; Kravets L; Boyd AW
J Biol Chem; 1998 Aug; 273(32):20228-37. PubMed ID: 9685371
[TBL] [Abstract][Full Text] [Related]
9. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Vail ME; Murone C; Tan A; Hii L; Abebe D; Janes PW; Lee FT; Baer M; Palath V; Bebbington C; Yarranton G; Llerena C; Garic S; Abramson D; Cartwright G; Scott AM; Lackmann M
Cancer Res; 2014 Aug; 74(16):4470-81. PubMed ID: 25125683
[TBL] [Abstract][Full Text] [Related]
10. The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization.
Stapleton D; Balan I; Pawson T; Sicheri F
Nat Struct Biol; 1999 Jan; 6(1):44-9. PubMed ID: 9886291
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.
Andretta E; Cartón-García F; Martínez-Barriocanal Á; de Marcondes PG; Jimenez-Flores LM; Macaya I; Bazzocco S; Bilic J; Rodrigues P; Nieto R; Landolfi S; Ramon Y Cajal S; Schwartz S; Brown A; Dopeso H; Arango D
Sci Rep; 2017 Feb; 7():41576. PubMed ID: 28169277
[TBL] [Abstract][Full Text] [Related]
12. Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3.
Day B; To C; Himanen JP; Smith FM; Nikolov DB; Boyd AW; Lackmann M
J Biol Chem; 2005 Jul; 280(28):26526-32. PubMed ID: 15901737
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics.
Li E; Hristova K
Cell Adh Migr; 2010; 4(2):249-54. PubMed ID: 20168077
[TBL] [Abstract][Full Text] [Related]
14. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3).
Davis TL; Walker JR; Loppnau P; Butler-Cole C; Allali-Hassani A; Dhe-Paganon S
Structure; 2008 Jun; 16(6):873-84. PubMed ID: 18547520
[TBL] [Abstract][Full Text] [Related]
15. PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling.
Mansour M; Nievergall E; Gegenbauer K; Llerena C; Atapattu L; Hallé M; Tremblay ML; Janes PW; Lackmann M
J Cell Sci; 2016 Jan; 129(2):277-89. PubMed ID: 26644181
[TBL] [Abstract][Full Text] [Related]
16. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3.
Lahtela J; Corson LB; Hemmes A; Brauer MJ; Koopal S; Lee J; Hunsaker TL; Jackson PK; Verschuren EW
Cell Cycle; 2013 Feb; 12(4):625-34. PubMed ID: 23324396
[TBL] [Abstract][Full Text] [Related]
17. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.
Vearing C; Lee FT; Wimmer-Kleikamp S; Spirkoska V; To C; Stylianou C; Spanevello M; Brechbiel M; Boyd AW; Scott AM; Lackmann M
Cancer Res; 2005 Aug; 65(15):6745-54. PubMed ID: 16061656
[TBL] [Abstract][Full Text] [Related]
18. EphA3 inhibits migration and invasion of esophageal cancer cells by activating the mesenchymal‑epithelial transition process.
Chen X; Lu B; Ma Q; Ji CD; Li JZ
Int J Oncol; 2019 Feb; 54(2):722-732. PubMed ID: 30483759
[TBL] [Abstract][Full Text] [Related]
19. Distinctive Structure of the EphA3/Ephrin-A5 Complex Reveals a Dual Mode of Eph Receptor Interaction for Ephrin-A5.
Forse GJ; Uson ML; Nasertorabi F; Kolatkar A; Lamberto I; Pasquale EB; Kuhn P
PLoS One; 2015; 10(5):e0127081. PubMed ID: 25993310
[TBL] [Abstract][Full Text] [Related]
20. The Neural Cell Adhesion Molecule (NCAM) Promotes Clustering and Activation of EphA3 Receptors in GABAergic Interneurons to Induce Ras Homolog Gene Family, Member A (RhoA)/Rho-associated protein kinase (ROCK)-mediated Growth Cone Collapse.
Sullivan CS; Kümper M; Temple BS; Maness PF
J Biol Chem; 2016 Dec; 291(51):26262-26272. PubMed ID: 27803162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
